Creo Medical Share Discussion Threads

[bloomberg2] 17/4/2024 12:35

Robotic surgery get the nod for further investment in the NHS !! Sunak says At Q&A Westminster

[nimbo10] 12/4/2024 16:32

Drop without much volume and getting close to year results, MMs looking for cheap shares before update.

[bloomberg2] 12/4/2024 16:14

Crazy price drop !! Unless something sinister in the background!! Technology cutting edge !! Sorry couldn't resist that one

[master investor] 10/4/2024 23:29

It will be a NICE surprise when the rns drops that's for sure.

[pacsltd] 10/4/2024 22:15

Funding is indeed not an issue in this case. Not sure if a sale is nailed on though.
I think holders are going to be in for a nice surprise this year.

[master investor] 10/4/2024 21:21

That is incorrect. You need to do more research. Funding is not an issue, and a sale is nailed on in the next 12-18 months

[peterrr3] 10/4/2024 19:21

There is a logical fit with Intuitive which is a key reason I hold a few, but I would prefer them to get into bed as a bolt on the than be taken out. Unfortunately I think they didn't raise enough last time so unless a deal like that is done they will be coming around cap in hand inside the year.

[bloomberg2] 08/4/2024 16:08

Hope so !!

[up to the moon and back] 08/4/2024 15:47

Yeah great volume and increase , this particular share has a great future ahead .

[bloomberg2] 08/4/2024 09:02

Nice start

[hatfullofsky] 04/4/2024 10:47

GDR got a NICE recommendation but 12 months from draft guidance. We're still "awaiting development" Since May 2023


NICE recommended in the May 2023 draft guidance. Following a public consultation of this draft guidance, which ends on 26 April 2024, final recommendations are expected to be published by NICE on 10 July 2024.

recommended in draft guidance that the Genedrive® CYP2C19-ID test should be used as the point-of-care ("POC") test of choice before clopidogrel administration in the management of Ischemic Stroke ("IS") and Transient Ischaemic Attack ("TIA") patients.

[edwardt] 03/4/2024 20:17

But perky today..

[dr biotech] 29/3/2024 11:47

One investor implies they will be taken out by intuitive

[dr biotech] 26/3/2024 13:40

from about 12mins

[bloomberg2] 26/3/2024 12:54

Does Creo get a mention

[edwardt] 26/3/2024 11:29

nice plug for creo...

[innnovate] 15/3/2024 20:20

I asked NICE MedTech how long appraisals are taking: ‘When the topic commences the estimated time is usually 1 year. It is topic dependant.’

If anyone has contacts at Creo, good to get their view on NICE timing and how critical they see NICE approval to meaningful market penetration in UK.

[wan] 15/3/2024 16:53

And the backdrop in the US is quite positive -

US hospitals predict uptick in procedures as staffing pressures ease
The forecast and a small overall rise in budgets could benefit Boston Scientific, Medtronic and Stryker, BTIG analysts said.

Published March 14, 2024

The answers about hospital spending contain better news for Intuitive. Robotic surgery was third on the list of spending priorities this year, behind facilities/construction and surgical equipment, and experienced the biggest year-over-year increase of any category. The change comes as Intuitive prepares to launch its next-generation surgical robot.

BTIG analysts listed Intuitive among the companies that could benefit from the trends detected in the survey. The analysts named Boston Scientific, Medtronic, Stryker, GE Healthcare, Accuray and Siemens Healthineers as other companies that may benefit.
Full story -

[wan] 15/3/2024 16:47

DIVE BRIEF
Intuitive lands FDA clearance for new da Vinci robot
The soft tissue robotics leader incorporated new features into the system, from tissue sensing feedback to a smaller size and more comfortable console.

Published March 15, 2024

Dive Brief:
Intuitive Surgical said Thursday it received 510(k) clearance from the Food and Drug Administration for a fifth-generation robotic surgery system intended to help the company keep its dominant market share in the face of looming competition.

The da Vinci 5 system incorporates features that surgeons have long sought, such as feedback that simulates the feel of the patient’s body tissue, a smaller physical footprint in the operating room, and better console ergonomics.

The improvements “can help drive incremental demand for the system and raise the bar for competition in the future,” William Blair analyst Brandon Vazquez said Friday in a note to clients.
Full story -

[wan] 15/3/2024 16:35

Intuitive Announces FDA Clearance of Fifth-Generation Robotic System, da Vinci 5
March 14, 2024



As Edison's recent update noted:
should the collaboration roll-over to include Intuitive's da Vinci systems (installed base of 8,606 systems), the market opportunity can be materially larger. We note that Creo is entitled to milestone and royalty payments as part of the collaboration (c £1.8m licensing fee in 2023). We view this as an exciting development and await further updates from the company.

[hatfullofsky] 15/3/2024 09:13

No NICE approval anytime soon I'm afraid. Check the post from Innovate and status still - in Awaiting Development

[bloomberg2] 14/3/2024 19:47

Nice approval this month ! Guess rise this morning !! followed be dip then rise again !! Just a hunch ??

[pacsltd] 14/3/2024 17:54

Why do you think there will be an RNS in the morning?

[bloomberg2] 14/3/2024 16:18

RNS in the morning